This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Metadate CD CII
Shire Pharmaceuticals Group PLC
Drug Names(s): Equasym XL, methylphenidate HCL extended release capsule
Description: BioMedTracker has a separate drug profile for Metadate ER Tablets CII.
Metadate CD CII is an extended release capsule formulation of methylphenidate, the active ingredient in Ritalin (R), containting both immediate-release (IR) and extended-release (ER) beads such that 30% of the dose is provided by the IR component and 70% of the dose is provided by the ER component. Metadate CD CII is given once-daily.
Methylphenidate is a central nervous system (CNS) stimulant that has a calming effect on many children who have ADHD. Although the precise mechanism of action is not known, it is thought to inhibit the reuptake of norepinephrine and dopamine in the presynaptic neuron (the neuron that is stimulating/inhibiting the connecting neuron) and increase release of these chemicals into the space outside the neurons.
Deal Structure: Between 1996 and 1999, Eurand entered into a series of agreements with Medeva, subsequently known as Celltech Group and now known as UCB, ultimately resulting in the execution of a development, license and supply agreement in June 1999. Eurand and UCB developed a sustained release formulation of Methylphenidate Hydrochloride. They also agreed to allow UCB to package, market and sell that developed product in exchange for the exclusive right to manufacture that product for a minimum period of ten years and UCB's agreement to pay Eurand royalties on all sales of the developed product.
In 2003, UCB ceased both ordering the developed product from Eurand and paying royalties. As a result, Eurand commenced an action against UCB claiming, among other things, breach of contract. UCB subsequently filed a counterclaim claiming breach of contract as well.
In August 2008, Eurand and UCB settled the litigation concerning the 1999 agreement. The settlement paid Eurand a total of $35...See full deal structure in Biomedtracker
Partners: UCB SA
Metadate CD CII News
Pink Sheet FDA BASIC RESEARCH ON SOLUBLE CD4
Pink Sheet Applied Immune Sciences
Pink Sheet Genentech orphan status for CD4
Additional information available to subscribers only: